CN1486698A - 含有二甲双胍和格列本脲的固体口服剂型 - Google Patents

含有二甲双胍和格列本脲的固体口服剂型 Download PDF

Info

Publication number
CN1486698A
CN1486698A CNA031092314A CN03109231A CN1486698A CN 1486698 A CN1486698 A CN 1486698A CN A031092314 A CNA031092314 A CN A031092314A CN 03109231 A CN03109231 A CN 03109231A CN 1486698 A CN1486698 A CN 1486698A
Authority
CN
China
Prior art keywords
glibenclamide
dosage form
solid oral
metformin
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA031092314A
Other languages
English (en)
Chinese (zh)
Inventor
Y�����ķ
Y·伯赫姆
�������ɭ
G·尼克尔森
G·卡维
S·J·尼克尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1486698(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Publication of CN1486698A publication Critical patent/CN1486698A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA031092314A 1998-07-15 1999-07-12 含有二甲双胍和格列本脲的固体口服剂型 Pending CN1486698A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401781A EP0974356B1 (en) 1998-07-15 1998-07-15 Tablets comprising a combination of metformin and glibenclamide
EP98401781.4 1998-07-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB998013625A Division CN1146427C (zh) 1998-07-15 1999-07-12 含有二甲双胍和格列本脲的固体口服剂型

Publications (1)

Publication Number Publication Date
CN1486698A true CN1486698A (zh) 2004-04-07

Family

ID=8235441

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA031092314A Pending CN1486698A (zh) 1998-07-15 1999-07-12 含有二甲双胍和格列本脲的固体口服剂型
CNB998013625A Expired - Lifetime CN1146427C (zh) 1998-07-15 1999-07-12 含有二甲双胍和格列本脲的固体口服剂型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB998013625A Expired - Lifetime CN1146427C (zh) 1998-07-15 1999-07-12 含有二甲双胍和格列本脲的固体口服剂型

Country Status (27)

Country Link
US (2) US6303146B1 (enExample)
EP (4) EP0974356B1 (enExample)
JP (2) JP2002520371A (enExample)
KR (2) KR20040053177A (enExample)
CN (2) CN1486698A (enExample)
AP (1) AP1450A (enExample)
AR (2) AR013052A1 (enExample)
AT (1) ATE250418T1 (enExample)
AU (2) AU753604B2 (enExample)
BR (1) BR9906600A (enExample)
CA (1) CA2303537C (enExample)
DE (1) DE69818444T2 (enExample)
DK (1) DK0974356T3 (enExample)
DZ (1) DZ2846A1 (enExample)
ES (1) ES2206868T3 (enExample)
ID (1) ID25784A (enExample)
MA (1) MA24930A1 (enExample)
MY (1) MY129552A (enExample)
NZ (1) NZ503248A (enExample)
OA (1) OA11400A (enExample)
PT (1) PT974356E (enExample)
RU (2) RU2226396C2 (enExample)
SI (1) SI0974356T1 (enExample)
TW (2) TW555560B (enExample)
UY (1) UY25611A1 (enExample)
WO (1) WO2000003742A2 (enExample)
ZA (1) ZA200001159B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094657B (zh) * 2004-12-31 2012-01-04 韩美药品株式会社 用于糖尿病药物的口服给药的控释复合制剂及其制备方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
IL149139A0 (en) * 1999-11-03 2002-11-10 Bristol Myers Squibb Co Pharmaceutical compositions containing metformin and glyburide
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
CA2725833A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP4353414B2 (ja) * 2001-07-30 2009-10-28 田辺三菱製薬株式会社 食後過血糖改善剤
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
DK1482919T3 (da) * 2002-01-25 2007-07-30 Silanes Sa De Cv Lab Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
ES2314227T7 (es) 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
EP1562607A1 (en) * 2002-11-15 2005-08-17 Ranbaxy Laboratories, Ltd. Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
JPWO2004091661A1 (ja) * 2003-04-15 2006-07-06 中外製薬株式会社 糖尿病治療剤
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
WO2008062273A2 (en) * 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Solid oral dosage form having antidiabetic drug combination
JO3272B1 (ar) 2007-07-19 2018-09-16 Takeda Pharmaceuticals Co مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد
CN101855344B (zh) 2007-07-26 2015-12-09 安姆根有限公司 修饰的卵磷脂-胆固醇酰基转移酶
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011135106A1 (es) * 2010-04-26 2011-11-03 Smart Pharma Solutions, S.L Granulado altamente dispersable para la preparación de formulaciones de sustancias activas de altas dosis y procedimiento de obtención del mismo
RU2451506C1 (ru) 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
EP2790729A4 (en) * 2011-12-12 2015-08-12 Orbis Biosciences Inc PARTICULATE FORMULATIONS WITH DELAYED RELEASE
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN105030793A (zh) * 2015-08-25 2015-11-11 瑞阳制药有限公司 二甲双胍格列本脲胶囊及其制备方法
WO2019070109A1 (es) * 2017-10-03 2019-04-11 Infinite Clinical Research International, S.A. De C.V. Triconjugado para el tratamiento de diabetes mellitus
JP2023528565A (ja) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
US12421245B2 (en) 2020-04-01 2025-09-23 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of GLP1 receptor agonist, and preparation method therefor
KR102484756B1 (ko) * 2020-11-13 2023-01-06 한국생산기술연구원 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362704C (de) * 1921-08-09 1922-11-02 Naamlooze Vennootschap Interna Vorrichtung zum Senken einer Last, insbesondere eines Rettungsbootes
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
IE63463B1 (en) * 1989-02-06 1995-04-19 Zeneca Ltd Phenylsulphone derivatives
GB9016978D0 (en) * 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
WO1998057634A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094657B (zh) * 2004-12-31 2012-01-04 韩美药品株式会社 用于糖尿病药物的口服给药的控释复合制剂及其制备方法

Also Published As

Publication number Publication date
ATE250418T1 (de) 2003-10-15
DZ2846A1 (fr) 2003-12-01
WO2000003742A2 (en) 2000-01-27
SI0974356T1 (en) 2003-12-31
CA2303537A1 (en) 2000-01-27
AU2003261560A1 (en) 2005-05-26
ID25784A (id) 2000-11-02
PT974356E (pt) 2004-02-27
MA24930A1 (fr) 2000-04-01
CN1146427C (zh) 2004-04-21
EP1011684A2 (en) 2000-06-28
DK0974356T3 (da) 2003-10-27
EP0974356B1 (en) 2003-09-24
US6303146B1 (en) 2001-10-16
KR20010030603A (ko) 2001-04-16
RU2226396C2 (ru) 2004-04-10
KR100478347B1 (ko) 2005-03-23
EP2269613A2 (en) 2011-01-05
DE69818444T2 (de) 2004-05-06
TW200303208A (en) 2003-09-01
AP2000001757A0 (en) 2000-03-31
AR065970A2 (es) 2009-07-15
TW555560B (en) 2003-10-01
JP2003292443A (ja) 2003-10-15
CA2303537C (en) 2005-12-06
AR013052A1 (es) 2000-11-22
BR9906600A (pt) 2000-07-18
EP2269613A3 (en) 2012-10-17
EP1435240A3 (en) 2009-08-12
USRE38629E1 (en) 2004-10-19
CN1275082A (zh) 2000-11-29
TWI245632B (en) 2005-12-21
OA11400A (en) 2004-04-08
EP1435240A2 (en) 2004-07-07
ZA200001159B (en) 2001-05-31
RU2003126257A (ru) 2005-02-27
UY25611A1 (es) 2000-08-21
RU2286788C2 (ru) 2006-11-10
DE69818444D1 (de) 2003-10-30
KR20040053177A (ko) 2004-06-23
MY129552A (en) 2007-04-30
AU753604B2 (en) 2002-10-24
WO2000003742A3 (en) 2000-04-20
AP1450A (en) 2005-07-25
ES2206868T3 (es) 2004-05-16
JP2002520371A (ja) 2002-07-09
NZ503248A (en) 2002-09-27
EP0974356A1 (en) 2000-01-26
AU5417999A (en) 2000-02-07

Similar Documents

Publication Publication Date Title
CN1146427C (zh) 含有二甲双胍和格列本脲的固体口服剂型
KR960005141B1 (ko) 서방성 제제
KR20080007357A (ko) 압축성이 열등한 치료학적 화합물을 갖는 조성물을제조하는 압출방법
CN1276718A (zh) 快速崩解的甲基纤维素片剂
CN1023191C (zh) 生产持续释放异丁丙苯酸制剂的方法
CN103301084B (zh) 一种盐酸小檗碱片及其制备方法
CN102188429A (zh) 一种治疗糖尿病的药物组合物
US20030104059A1 (en) Controlled release tablets of metformin
CN101167731A (zh) 含有二甲双胍和格列本脲的分散片及其制备方法
JP2004525109A (ja) 安定化された甲状腺ホルモン医薬組成物、及びその製法
GR1009644B (el) Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
WO2006123213A1 (en) Modified release formulations of gliclazide
CN101168060B (zh) 一种含双胍和磺酰脲的稳定的药物组合物及其制备方法
CN1742730A (zh) 高溶出度的盐酸二甲双胍格列吡嗪胶囊的制备方法
CN100455279C (zh) 口服延迟释放锭剂组成物及其制法
CN1309376C (zh) 麝香缓、控释制剂及其制备方法
CN1732911A (zh) 琥珀酸亚铁缓释制剂及其制备方法
CN119970667A (zh) 一种依帕司他缓释片及其制备方法
CN101045039A (zh) 糖尿病治疗剂型
WO2004091587A1 (en) Multiple release anti-diabetic drugs and process of production thereof
MXPA00002568A (en) Solid oral dosage form comprising a combination of metformin and glibenclamide
CN1712015A (zh) 司他夫定缓释片及制备工艺
AU2002348712A1 (en) Dosage form for treatment of diabetes mellitus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication